OncoMed Pharmaceuticals Receives Patent on MAbTrap Antibody Technology
OncoMed Pharmaceuticals has been granted its first US patent on its MAbTrap antibody display technology.
OncoMed Pharmaceuticals, a clinical-stage company developing therapeutics that target cancer stem cells, has been granted its first US patent on its MAbTrap antibody display technology. OncoMed's MAbTrap technology enables the identification of monoclonal antibodies that bind a particular target or set of targets, and bind such target or targets with high affinity and specificity. OncoMed has used the patented technology to identify and/or optimize antibodies, including proprietary bispecific antibodies, and demonstrated the activity of these antibodies in preclinical studies.
The new patent, US Patent No. 8,551,715, relates to methods of producing libraries of cells that express membrane-bound antibodies or other specific binding agents on their surface, and methods of identifying the cells in such libraries that express an antibody or other agent having the desired binding characteristics. The patented methods include mammalian cell display methods. Related patent applications are currently pending in the United States, Europe, Japan, and China. The new patent and related applications are all solely owned byOncoMed.
Source: OncoMed Pharmaceuticals
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
